| Title |
Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
|
|---|---|
| Published in |
Diabetes Therapy, August 2014
|
| DOI | 10.1007/s13300-014-0076-9 |
| Pubmed ID | |
| Authors |
Jiten Vora, Torsten Christensen, Azhar Rana, Steve C. Bain |
| Abstract |
Insulin degludec (degludec) is a basal insulin with an ultra-long, stable action profile and reduced pharmacodynamic variability. Seven phase 3a trials compared degludec with insulin glargine (glargine). Patient-level meta-analyses were performed to obtain a comprehensive overview of differences between the insulin preparations, possible because consistent outcome definitions were utilized. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 75 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 13% |
| Other | 9 | 12% |
| Student > Master | 9 | 12% |
| Student > Bachelor | 9 | 12% |
| Student > Postgraduate | 7 | 9% |
| Other | 18 | 24% |
| Unknown | 13 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 9% |
| Agricultural and Biological Sciences | 4 | 5% |
| Economics, Econometrics and Finance | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Other | 8 | 11% |
| Unknown | 15 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 May 2023.
All research outputs
#6,491,148
of 23,864,690 outputs
Outputs from Diabetes Therapy
#254
of 1,045 outputs
Outputs of similar age
#58,919
of 231,985 outputs
Outputs of similar age from Diabetes Therapy
#3
of 7 outputs
Altmetric has tracked 23,864,690 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,045 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 231,985 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.